Home > Boards > US OTC > Medical - Drugs > PLUS Therapeutics (PSTV)

NEWS -- Plus Therapeutics to Present at the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 75
Posts 10,618
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021 GlobeNewswire Inc. - 4/8/2021 7:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/5/2021 5:07:05 PM
Plus Therapeutics and Piramal Pharma ink master services agreement Seeking Alpha - 3/24/2021 12:15:32 PM
Plus Therapeutics (PSTV) shares surge 48% on Rhenium NanoLiposome deal Seeking Alpha - 3/23/2021 7:41:12 AM
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Man... GlobeNewswire Inc. - 3/23/2021 7:30:00 AM
Plus Therapeutics to Participate in Upcoming Virtual Conferences GlobeNewswire Inc. - 3/18/2021 7:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/12/2021 4:15:14 PM
Plus Therapeutics to Participate in Upcoming Virtual Conferences GlobeNewswire Inc. - 3/3/2021 7:30:00 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 2/26/2021 4:29:35 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/26/2021 12:41:15 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/26/2021 10:11:02 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/23/2021 4:28:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/23/2021 4:07:08 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/22/2021 4:19:42 PM
Plus Therapeutics EPS misses by $1.46 Seeking Alpha - 2/22/2021 4:13:43 PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights GlobeNewswire Inc. - 2/22/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 4:06:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 4:06:15 PM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 20... GlobeNewswire Inc. - 2/11/2021 4:15:00 PM
Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference GlobeNewswire Inc. - 2/11/2021 7:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 3:23:05 PM
Plus Therapeutics keeps soaring after trading halt Seeking Alpha - 2/10/2021 12:20:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2021 6:55:04 AM
Plus Therapeutics to Participate in Upcoming January Conferences GlobeNewswire Inc. - 1/5/2021 4:15:00 PM
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECTâ„¢ Glioblastoma Trial GlobeNewswire Inc. - 12/15/2020 7:30:00 AM
Paulness   Thursday, 11/12/20 08:13:50 AM
Re: None
Post # of 178 
NEWS -- Plus Therapeutics to Present at the virtual Fall Investor Summit on November 16th-18th

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Plus Therapeutics (NASDAQ:PSTV), is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets, including recurrent glioblastoma. PSTV will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at http://plustherapeutics.com and http://respect-trials.com.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker (mailto://brittney@investorsummitgroup.com)

To request complimentary investor registration: please visit our website at http://www.investorsummitgroup.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at mailto://brittney@investorsummitgroup.com

SOURCE: Plus Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/615981/Plus-Therapeutics-to-Present-at-the-virtual-Fall-Investor-Summit-on-November-16th-18th

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences